You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Claims for Patent: 9,993,461

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,993,461

Title:	Method for treating disorders associated with glomerular function
Abstract:	Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
Inventor(s):	Jinkun Zhang, Zofia E. Dziewanowska, Rene Belder, Ian Henderson, Joseph B. Bogardus, Zhaoying Zhang
Assignee:	Ligand Pharmaceuticals Inc
Application Number:	US15/687,407
Patent Claims:	1. A method of treating a disorder selected from the group consisting of glomerulosclerosis and IGA nephropathy, comprising administering to a subject in need thereof an effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is from 200 mg/day to 800 mg/day. 2. The method according to claim 1, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day, 400 mg/day or 800 mg/day. 3. The method according to claim 1, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day. 4. The method according to claim 1, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 400 mg/day. 5. The method according to claim 1, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 800 mg/day. 6. The method according to claim 1, wherein the disorder is glomerulosclerosis. 7. The method according to claim 1, wherein the disorder is IGA nephropathy. 8. The method according to claim 7, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day, 400 mg/day or 800 mg/day. 9. The method according to claim 7, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day. 10. The method according to claim 7, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 400 mg/day. 11. The method according to claim 7, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 800 mg/day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.